ClinicalTrials.gg
CompletedNCT04542772Updated Oct 5, 2026

Mirror Therapy Education for Acute Stroke Patients

An interventional study of Mirror Therapy and Regular Rehabilitation in Stroke, Acute, sponsored by Health Sciences North Research Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Health Sciences North Research Institute · Not applicable, Interventional, and Health services research

How we know

Updated Oct 5, 2026Now CompletedFirst site in Canada+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 444 studies in Stroke with a site in Canada — 83 open to participants now, 99 under way, 13 of them phase 3. Stroke · Canada.

Enrollment
306th of 374
20 · median 74
Started
2022
with 23 others
No phase
224 of 444
50 open now
Registered
322nd of 444
by date

Among the 444 studies in Stroke with a site in Canada, this one is the 306th largest by enrollment of the 374 interventional ones that give a count, is one of 24 that started in 2022, is one of 224 with no phase, and was the 322nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

83 of the 444 studies in Stroke with a site in Canada are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 444 studies in Stroke with a site in Canada, or all of them as a file.
02

Study summary

In Canada, the number of stroke survivors is equivalent to the size of one of the four Atlantic Provinces. The incident rate of stroke has been increasing steadily since 1995. The majority of the stroke survivors lose upper extremity function, resulting in diminished activities of daily living (ADL). Many therapeutic interventions are recommended to improve upper extremity function or ADLs of stroke survivors, however, Mirror Therapy (MT), inexpensive intervention, can be self-administered by stroke survivors with intact cognition. Thus, the research question is whether a self-administered MT technique improves acute stroke patients' upper extremity motor function and recovery?

03

Conditions studied

  • Stroke, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted with diagnosis of stroke with onset within two weeks
  • Medically stable
  • Able to follow directions
  • No severe cognitive impairments that could interfere with patient participation
  • Consent to treatment by patient
  • Alpha-Functional Independence Measure (Alpha-FIM) score of > 40

Exclusion criteria

Exclusion Criteria:

  • Medical instability
  • Lack of motivation
  • Recurrent/ chronic stroke
  • Recent upper extremity musculoskeletal injuries with movement restrictions
  • Receptive or global aphasia
  • Delirium
  • Unilateral neglect
  • Visual field deficiency.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Mirror Therapy + Standard of Care

    Participants in this group will receive standard of care based on their needs along with mirror therapy education.

    Other: Mirror Therapy · Other: Regular Rehabilitation

  • Active comparator
    Standard of Care

    Participants in this group will receive only standard of care based on their needs.

    Other: Regular Rehabilitation

Interventions

  • OtherMirror Therapy

    Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.

  • OtherRegular Rehabilitation

    Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment scale

    Scores of \< 31 corresponded with 'no to poor' upper extremity capacity, 32 to 47 represented 'limited capacity', 48 to 52 represented 'notable capacity' and 53 to 66 represented 'full' upper extremity capacity.

    Time frame: Assessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeks.

  2. Wolf Motor Function Test

    Assess upper extremity function; maximum Score is 75; lower scores are indicative of lower functional levels.

    Time frame: : Assessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeks

Secondary outcomes

  1. Modified Barthel Index

    Assess Activity of Daily Living, Scores of \<15 usually represents moderate disability and \<10 usually represents severe disability.

    Time frame: : Assessment will be completed at 2 points: Pre-test assessment will be done within 48 hours of stroke admission and post-test assessment will be done at 4 weeks

07

Study locations

1 site
  • Health Sciences North
    Greater Sudbury, Ontario P3E 5J1, Canada
08

References and documents

Publications

  • Rajendran V, Jeevanantham D, Lariviere C, Singh RJ, Zeman L, Papuri P. Effectiveness of self-administered mirror therapy on upper extremity impairments and function of acute stroke patients: study protocol. Trials. 2021 Jul 9;22(1):439. doi: 10.1186/s13063-021-05380-9. PubMed 34243808 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2024, 21 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 21 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start May 2021 → Jul 2022, primary completion Sep 2021 → May 2024 and completion Sep 2021 → May 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Sep 9, 2020
StartActual
Jul 4, 2022was May 2021
Primary completionActual
May 3, 2024was Sep 2021
CompletionActual
May 3, 2024was Sep 2021
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 5, 2026
Sites
1 site added — first site in Canada
Show site
  • Health Sciences North · Greater Sudbury, Canada
Oct 5, 2026
Start date
May 2021→Jul 4, 2022 (actual)
Oct 5, 2026
Primary completion
Sep 2021→May 3, 2024 (actual)
Oct 5, 2026
Study completion
Sep 2021→May 3, 2024 (actual)
Oct 5, 2026
Enrollment
36 (estimated)→20 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Status unknown→Completed
    1 site added — first site in Canada
    Show site
    • Health Sciences North · Greater Sudbury, Canada
    Start date May 2021→Jul 4, 2022 (now actual)
    Primary completion Sep 2021→May 3, 2024 (now actual)
    Study completion Sep 2021→May 3, 2024 (now actual)
    Enrollment 36 (estimated)→20 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04542772
Lead sponsor
Health Sciences North Research Institute
Collaborators
NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATION (NOAMA)
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Jul 4, 2022
Primary completion
May 3, 2024
Completion
May 3, 2024
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion